WALTHAM, Mass., November 29, 2018 – As part of the company’s annual grant program to support research to reduce preterm birth and preeclampsia and associated complications, AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it has awarded four grants totaling nearly $300,000 to independent researchers in the maternal health field.
“AMAG is committed to advancing research in high-risk pregnancies, including for the treatment of preterm birth and severe preeclampsia. We recently announced our plans to study a potential treatment for severe preeclampsia, a serious pregnancy complication and a leading cause of maternal and neonatal mortality, for which there are currently no FDA-approved treatment options,” said Brian Robinson, MD, senior vice president of medical affairs at AMAG. “With November marking Prematurity Awareness Month, it’s an important time to reflect on the need for ongoing research for this underserved patient population. Our annual Research Grants Program in maternal health allows us to support independent researchers studying preterm birth and preeclampsia.”
The 2018 grant recipients were selected by an independent external review panel of maternal fetal medicine specialists with extensive research experience. The panel was chaired by George Saade, MD, Professor, Obstetrics/Gynecology and Cell Biology at The University of Texas Medical Branch.
“The number of quality submissions for AMAG’s Research Grants Program in maternal health, now in its fifth consecutive year, continues to be impressive year-over-year,” said Dr. Saade. “Independent research grants are important to advancing medicine and with AMAG’s support, researchers can explore novel ways to help address serious maternal-fetal health issues.”
The following five investigators and studies have been awarded grants:
- Monica Longo, MD, PhD, Associate Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth), and Biana Godin, MScPharm, PhD, Assistant Professor of Nanomedicine, Institute for Academic Medicine Assistant Member, Houston Methodist Research Institute Department of Nanomedicine, Department of Obstetrics & Gynecology Houston Methodist Hospital are both researching nanomedicine for renal protection and prevention of fetal toxicities of enalapril during pregnancy complicated by chronic hypertension and preeclampsia;
- Anna Palatnik, MD, Assistant Professor at the Medical College of Wisconsin, Department of Obstetrics and Gynecology, who is researching the role of micro-RNA 223 in the pathogenesis of preeclampsia;
- Sarah England, PhD, Professor of Medicine and OB/GYN at Washington University School of Medicine in St. Louis, Department of Obstetrics and Gynecology, who is researching the physiological consequences of oxytocin receptor variants and their role in preterm birth; and
- Maisa Feghali, MD, MSCR, Assistant Professor at the University of Pittsburgh School of Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, who is researching metformin for the prevention of hypertensive disorders of pregnancy in women with Type 1 diabetes mellitus at the Magee-Womens Research Institute and Foundation.
AMAG is a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs. The company does this by leveraging its development and commercial expertise to invest in and grow its pharmaceutical products across a range of therapeutic areas, including women’s health. For additional company information, please visit www.amagpharma.com.
This press release contains forward-looking information about AMAG Pharmaceuticals, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, AMAG’s belief that independent research grants are important to advancing medicine and with AMAG’s support, clinicians can explore novel ways to help address serious maternal-fetal health issues are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.
Such risks and uncertainties include, among others, those risks identified in AMAG’s filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2017, its Quarterly Reports on Form 10-Q for the quarters ending June 30, 2018 and September 30, 2018 and subsequent filings with the SEC. Any such risks and uncertainties could materially and adversely affect AMAG’s results of operations, its profitability and its cash flows, which would, in turn, have a significant and adverse impact on AMAG’s stock price. AMAG cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.
AMAG disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. Contacts:
Associate Director, Investor Relations
Vice President, Corporate Affairs